Elucidation of the structure and intermolecular interactions of a reversible cyclic-peptide inhibitor of the proteasome by NMR spectroscopy and molecular modeling

Research output: Contribution to journalArticleResearchpeer review

Authors

  • Benjamin Stauch
  • Bernd Simon
  • Teodora Basile
  • Gisbert Schneider
  • Nisar P. Malek
  • Markus Kalesse
  • Teresa Carlomagno

External Research Organisations

  • European Molecular Biology Laboratory
  • ETH Zurich
  • Hannover Medical School (MHH)
  • Helmholtz Centre for Infection Research (HZI)
View graph of relations

Details

Original languageEnglish
Pages (from-to)3934-3938
Number of pages5
JournalAngewandte Chemie - International Edition
Volume49
Issue number23
Publication statusPublished - 25 May 2010
Externally publishedYes

Abstract

chemical equation presentation Complex considerations: The proteasome plays a key role in diseases and is thus an appealing drug target. A structural model (see picture) of the proteasome as a complex with argyrin, a cyclic heptapeptide with antitumoral activity, provides a rationale for the high biological activity of this natural product. The structure-activity-relationship data available for the drug are discussed on the basis of this model.

Keywords

    Cancer, Competitive binding, Ligand interactions, Nmr spectroscopy, Proteasomes

ASJC Scopus subject areas

Sustainable Development Goals

Cite this

Elucidation of the structure and intermolecular interactions of a reversible cyclic-peptide inhibitor of the proteasome by NMR spectroscopy and molecular modeling. / Stauch, Benjamin; Simon, Bernd; Basile, Teodora et al.
In: Angewandte Chemie - International Edition, Vol. 49, No. 23, 25.05.2010, p. 3934-3938.

Research output: Contribution to journalArticleResearchpeer review

Download
@article{e6f85991adfc4262a7816555fe432704,
title = "Elucidation of the structure and intermolecular interactions of a reversible cyclic-peptide inhibitor of the proteasome by NMR spectroscopy and molecular modeling",
abstract = "chemical equation presentation Complex considerations: The proteasome plays a key role in diseases and is thus an appealing drug target. A structural model (see picture) of the proteasome as a complex with argyrin, a cyclic heptapeptide with antitumoral activity, provides a rationale for the high biological activity of this natural product. The structure-activity-relationship data available for the drug are discussed on the basis of this model.",
keywords = "Cancer, Competitive binding, Ligand interactions, Nmr spectroscopy, Proteasomes",
author = "Benjamin Stauch and Bernd Simon and Teodora Basile and Gisbert Schneider and Malek, {Nisar P.} and Markus Kalesse and Teresa Carlomagno",
year = "2010",
month = may,
day = "25",
doi = "10.1002/anie.201000140",
language = "English",
volume = "49",
pages = "3934--3938",
journal = "Angewandte Chemie - International Edition",
issn = "1433-7851",
publisher = "John Wiley and Sons Ltd",
number = "23",

}

Download

TY - JOUR

T1 - Elucidation of the structure and intermolecular interactions of a reversible cyclic-peptide inhibitor of the proteasome by NMR spectroscopy and molecular modeling

AU - Stauch, Benjamin

AU - Simon, Bernd

AU - Basile, Teodora

AU - Schneider, Gisbert

AU - Malek, Nisar P.

AU - Kalesse, Markus

AU - Carlomagno, Teresa

PY - 2010/5/25

Y1 - 2010/5/25

N2 - chemical equation presentation Complex considerations: The proteasome plays a key role in diseases and is thus an appealing drug target. A structural model (see picture) of the proteasome as a complex with argyrin, a cyclic heptapeptide with antitumoral activity, provides a rationale for the high biological activity of this natural product. The structure-activity-relationship data available for the drug are discussed on the basis of this model.

AB - chemical equation presentation Complex considerations: The proteasome plays a key role in diseases and is thus an appealing drug target. A structural model (see picture) of the proteasome as a complex with argyrin, a cyclic heptapeptide with antitumoral activity, provides a rationale for the high biological activity of this natural product. The structure-activity-relationship data available for the drug are discussed on the basis of this model.

KW - Cancer

KW - Competitive binding

KW - Ligand interactions

KW - Nmr spectroscopy

KW - Proteasomes

UR - http://www.scopus.com/inward/record.url?scp=77953012647&partnerID=8YFLogxK

U2 - 10.1002/anie.201000140

DO - 10.1002/anie.201000140

M3 - Article

C2 - 20408152

AN - SCOPUS:77953012647

VL - 49

SP - 3934

EP - 3938

JO - Angewandte Chemie - International Edition

JF - Angewandte Chemie - International Edition

SN - 1433-7851

IS - 23

ER -

By the same author(s)